In experimental peripheral arterial disease, type 2 diabetes alters post-ischemic gene expression

• Published in: Journal of clinical & translational endocrinology Vol. 17; p. 100199
• Main Authors: Peravali, Rahul, Gunnels, Lucas, Dhanabalan, Karthik, Ariganjoye, Folabi, Gerling, Ivan C., Dokun, Ayotunde O.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.09.2019; Elsevier
• Subjects: Genome-wide gene expression profiling; Molecular pathway analysis; Peripheral artery disease; Research Paper; Type 2 diabetes mellitus; Peripheral artery disease; Type 2 diabetes mellitus; Molecular pathway analysis; Genome-wide gene expression profiling
• ISSN: 2214-6237; 2214-6237
• DOI: 10.1016/j.jcte.2019.100199

Peripheral arterial disease is characterized by impaired blood flow to tissues outside the heart due to atherosclerosis and it most frequently occurs in the lower extremities. Type 2 diabetes (T2D) is a well-known risk factor that accelerate the course and contributes to poor clinical outcomes of PAD. While there is some evidence that T2D is associated with altered expression of genes involved in regulating PAD severity, our knowledge about the specific genes and pathways involved remains incomplete. We induced experimental PAD or hind limb ischemia in T2D and non-diabetic mice and subjected the ischemic gastrocnemius muscle tissues to genome-wide mRNA transcriptome analysis. We subsequently performed pathway analysis on the top 500 genes that showed the most significant expression differences between the ischemic diabetic and ischemic non-diabetic muscle tissues. Pathway analysis of the differentially expressed genes identified pathways involved in essential biological processes such as “metabolic pathways,” “phagosomes,” “lysosomes,” and “regulation of actin cytoskeleton”. Overall, our data provides the opportunity to test hypotheses on the potential role of the altered genes/molecular pathways in poor PAD outcomes in diabetes.